Display options
Cite
Robertson L, Santini H, O'Donovan KL, et al. Current Pharmacological Management in Juvenile Huntington's Disease. PLoS Curr. 2012;4:RRN1304doi: 10.1371/currents.RRN1304.
Robertson, L., Santini, H., O'Donovan, K. L., Squitieri, F., Barker, R. A., Rakowicz, M., Landwehrmeyer, G. B., & Quarrell, O. (2012). Current Pharmacological Management in Juvenile Huntington's Disease. PLoS currents, 4RRN1304. https://doi.org/10.1371/currents.RRN1304
Robertson, Lisa, et al. "Current Pharmacological Management in Juvenile Huntington's Disease." PLoS currents vol. 4 (2012): RRN1304. doi: https://doi.org/10.1371/currents.RRN1304
Robertson L, Santini H, O'Donovan KL, Squitieri F, Barker RA, Rakowicz M, Landwehrmeyer GB, Quarrell O. Current Pharmacological Management in Juvenile Huntington's Disease. PLoS Curr. 2012 Feb 15;4:RRN1304. doi: 10.1371/currents.RRN1304. PMID: 22474619; PMCID: PMC3283037.
Copy Download .nbib Format: NLM
Share it on

PLoS Curr. 2012 Feb 15;4:RRN1304. doi: 10.1371/currents.RRN1304.

Current Pharmacological Management in Juvenile Huntington's Disease.

PLoS currents

Lisa Robertson, Helen Santini, Kirsty L O'Donovan, Ferdinando Squitieri, Roger A Barker, Maria Rakowicz, G Bernhard Landwehrmeyer, Oliver Quarrell

Affiliations

  1. Department of Clinical Genetics, Sheffield Children's Hospital, Sheffield UK S10 2TH; Neurogenetics and Rare Diseases Centre, IRCCS Neuromed, Pozzilli (IS), Italy.; University of Cambridge; Department of Clinical Neurophysiology, Institute of Psychiatry and Naurology, Warsaw, Poland and Dept. of Neurology, University of Ulm, Ulm, Germany.

PMID: 22474619 PMCID: PMC3283037 DOI: 10.1371/currents.RRN1304

Abstract

BACKGROUND: The clinical presentation of Juvenile Huntington's Disease (JHD) can be very different from adult-onset HD with little evidence to guide symptomatic management.

AIM: To survey the current use of pharmacological treatments for JHD.

METHODS: Patients were identified through the HD Association, Hospital Doctors and the European Huntington's Disease Network REGISTRY study.

RESULTS: The most commonly prescribed agents were anti-psychotics (24/45), anti-depressants (17/45) and anti-parkinsonian medications (15/45). 5 patients were taking more than 8 medications.

CONCLUSIONS: The most commonly prescribed group of medication was the anti-psychotic. Many patients were on multiple therapies, highlighting the need to rationalise medications.

References

  1. Epileptic Disord. 2007 Dec;9(4):353-412 - PubMed
  2. Acta Neurol Scand. 1986 Oct;74(4):266-8 - PubMed
  3. Neurology. 1997 Oct;49(4):1048-53 - PubMed
  4. Arq Neuropsiquiatr. 2006 Mar;64(1):5-9 - PubMed
  5. Br J Psychiatry. 1970 Mar;116(532):241-53 - PubMed
  6. Acta Neurol Scand. 1980 Nov;62(5):305-11 - PubMed
  7. Lancet Neurol. 2011 May;10(5):446-56 - PubMed
  8. Ment Retard Dev Disabil Res Rev. 2001;7(3):153-7 - PubMed
  9. Neurology. 2003 Oct 28;61(8):1085-92 - PubMed
  10. Am J Med Genet B Neuropsychiatr Genet. 2004 Feb 15;125B(1):92-8 - PubMed
  11. Ann Oncol. 2010 Mar;21(3):615-626 - PubMed
  12. Lancet. 1984 May 19;1(8386):1100-2 - PubMed
  13. Arch Neurol. 1995 Aug;52(8):749-53 - PubMed
  14. Neuropediatrics. 2000 Aug;31(4):190-4 - PubMed
  15. Int J Palliat Nurs. 2005 Jun;11(6):278-83 - PubMed
  16. Eur J Neurol. 2003 Jul;10(4):443-4 - PubMed
  17. Neurobiol Dis. 1994 Dec;1(3):159-66 - PubMed
  18. Arch Neurol. 2007 Jun;64(6):813-9 - PubMed
  19. PLoS Curr. 2010 Sep 28;2: - PubMed
  20. Nat Genet. 1993 Aug;4(4):387-92 - PubMed
  21. Cell. 1993 Mar 26;72(6):971-83 - PubMed
  22. Hum Genet. 1986 Jul;73(3):235-9 - PubMed

Publication Types

Grant support